NASDAQ
1.50USD
-0.27 (-15.06%)
We have scored 3 news catalysts on Femasys Inc. (FEMY) over the past 12 months. The biggest single-day move next to one of them came Oct 14, 2026, when FEMY closed −15.4%: “Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall Cotton.”. Coverage across the window leans positive (average ticker sentiment +0.80). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.5M
P/E
—
EPS
—
Beta
-2.15
52W range
1.4801-22.2
Day range
1.49–1.75
Open
1.70
Prev close
1.76
Volume
140.2K
Avg volume
540.2K
Dividend
0.00
IPO
2021-06-18
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Femasys Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for FEMY: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
